Microwave tomography helps identify effectiveness of breast cancer treatment
Microwave imaging may be a useful way to monitor the effectiveness of breast cancer treatment.
Microwave tomography may be able to identify the effectiveness of breast cancer treatments at an early stage, enabling treatments to be changed in cases where the patient is not responding.
That is according to a study from Dartmouth-Hitchcock Medical Centre and published in BioMed Central's open access journal Breast Cancer Research.
The research showed age, breast density and body mass index did not obscure the results, which can be an issue with the use of other imaging techniques.
In fact, regions of high conductivity corresponded to the tumours and low conductivity corresponded to normal tissues, painting a clear view of the progress of the cancer.
"By recalling patients for scans during their treatment, we found that we could actually see tumours shrinking in women who responded to chemotherapy," said Paul Meany, who led the study.
He added: "Microwave tomography could therefore be used to identify women who are not responding to initial treatment and their treatment changed appropriately at an early stage."
The study was carried out on eight breast cancer patients who were being treated with chemotherapy until surgery.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...